• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
ProAxsis’ ProteaseTag® NE Immunoassay highlighted at BTS 2016
Share
Conferences, Neutrophil Elastase Immunoassay, News, ProteaseTag®

ProAxsis’ ProteaseTag® NE Immunoassay highlighted at BTS 2016

December 8, 2016
-
Posted by Webmaster

ProAxsis (www.proaxsis.com) was delighted to observe that measuring active neutrophil elastase (NE) by its ProteaseTag® Active NE Immunoassay was identified as a potential biomarker of bacterial exacerbation in COPD patients at this week’s British Thoracic Society conference in London. The respiratory team from the University of Oxford, with Samantha Thulborn as lead author, presented data on more than 120 sputum samples from patients with COPD, which highlighted statistically significant correlations between levels of neutrophil elastase, as measured by the ProteaseTag® Active NE Immunoassay, and other clinical symptoms including cough, dyspnoea and sputum purulence. The group also identified a clear association between active NE levels and bacterial infection.

Dr David Ribeiro, CEO of ProAxsis, said “Our ProteaseTag® Active NE Immunoassay continues to gain recognition as a valuable tool amongst researchers working in respiratory diseases such as COPD, cystic fibrosis and bronchiectasis. The team at the University of Oxford are well recognised as being experts in respiratory exacerbations, so it is very pleasing for us that they have incorporated our immunoassay in to their latest study, and shown such positive results.”

Any queries concerning ProAxsis’ Immunoassays for measuring active neutrophil elastase, or any other aspects of the company’s proprietary ProteaseTag® technology, can be directed to info@77.104.171.207.

ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.

December 8, 2016

Related News

Other posts that you should not miss.
Announcements, News

ProAxsis wins Innovative Business of the Year Award

June 4, 2018
-
Posted by David Ribeiro

ProAxsis Limited has been declared as the “Innovative Business of the Year” at the Business Eye First …

Read More
June 4, 2018
Posted by David Ribeiro
Conferences, NEATstik®

ProAxsis abstracts at 2017 British Thoracic Society Winter Meeting

December 5, 2017
-
Posted by Webmaster

ProAxsis’ ProteaseTag® technology will again be featured at the Winter meeting of the British Thoracic Society, which takes …

Read More
December 5, 2017
Posted by Webmaster
Announcements, News

ProAxsis appoints experienced Sales and Marketing Manager

April 20, 2016
-
Posted by Webmaster

ProAxsis is pleased to announce the appointment of Sarah Ganniclefft to the newly created role of Sales …

Read More
April 20, 2016
Posted by Webmaster
← PREVIOUS POST
ProteaseTag® Active Neutrophil Elastase Immunoassay used to predict future risk of exacerbation in bronchiectasis
NEXT POST →
ProAxsis to present at 2016 North American Cystic Fibrosis Conference
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis Limited appoints first distributor for DACH region
    December 14, 2020

    ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active …

  • ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19
    December 10, 2020

    ProAxsis (www.proaxsis.com), the Belfast-based respiratory diagnostics company, today announces that it has been …

  • ProAxsis Limited recognised as Gold Level Innovator by Innovate NI
    December 2, 2020

    ProAxsis (www.proaxsis.com), the Belfast-based protease diagnostics company, is delighted to announce that it …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • December 14, 2020
    ProAxsis Limited appoints first distributor for DACH region
  • December 10, 2020
    ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19
  • December 2, 2020
    ProAxsis Limited recognised as Gold Level Innovator by Innovate NI
LATEST TWEETS
Twitter
ProAxsis
Follow Me
ProAxsis is delighted to have received this support from Innovate UK - https://t.co/toTxOz9KK6
43 days ago
- ProAxsis
RT @GRobinsonDUP: I’m delighted that @ProAxsis based in East Belfast have been successful in their application for an Innovate UK Grant, wh…
43 days ago
- ProAxsis
We are delighted to announce that as of today, we have appointed an exclusive distributor for our portfolio of prod… https://t.co/rmCmIugsLa
64 days ago
- ProAxsis
Due to our continued expansion, we wish to recruit an Administration Officer. This post can be full-time or part-ti… https://t.co/k3wKwVfOKy
84 days ago
- ProAxsis
Copyright © 2016-2018 - ProAxsis - All rights reserved. 
ProAxsis’ ProteaseTag® NE Immunoassay highlighted at BTS 2016 | ProAxsis